Sofinnova leads €22.5m Gecko Biomedical round

Sofinnova has become the largest investor in Gecko following the round, which also saw participation from BPI France and previous investors Omnes Capital, CM-­CIC Innovation and CapDecisif Management. Sofinnova's Antoine Papiernik and BPI France's Chahra Louafi have joined the company's board.

The fresh funding will advance the development of Gecko's first platform, GB-02, primarily designed to address cardiovascular reconstruction. It will also be used to expand into additional areas including guided tissue repair and localised drug delivery.

Omnes, CM-CIC Capital Finance and CapDecisif backed the company's €8m series-A round in late 2013.

Company
Founded in 2013 and headquartered in Paris, Gecko develops biodegradable tissue adhesives and sealants for wound closure during surgery, with a particular focus on minimally invasive cardiovascular surgery – also known as keyhole surgery.

People
Sofinnova Partners – Antoine Papiernik (managing partner).
BPI France – Chahra Louafi (investment director).
Gecko Biomedical – Christophe Bancel (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• France
• Sofinnova
• Venture
• Omnes Capital
• BPI France